Penn Pharma is headquartered in Tredegar, Wales, and operates regional offices in New Hope, Pa., and Tokyo. Penn Pharma offers both drug development and manufacturing services, including clinical and commercial dosage form manufacturing, as well as clinical packaging, labeling and global storage, distribution and return drug services.
Recently, Penn Pharma opened a new purpose-built contained manufacturing facility in response to market need for specialist containment solutions for the development and manufacturing of solid oral dose products containing highly potent compounds. In 2014, Penn launched a capacity expansion project for large scale commercial manufacturing and packaging.
Penn Pharma's drug development, manufacturing and packaging services complement PCI's own growth in clinical trial and commercial supply services, having expanded both its global operations in North America and Europe. PCI has announced several investments, including Cold Chain infrastructure expansions for both storage and logistics as well as support for refrigerated packaging operations. PCI also will open a 97,000-square-foot, North American storage and distribution facility for investigational products in September.
